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Summary Twenty-seven patients with severe alopecia areata were treated with dapsone. The results of a mean
treatment duration of 10 ± 0-5 months are reported, and compared with the results of long-term 
topical immunotherapy obtained previously at the same institute. The efficacy of dapsone proved to 
be markedly inferior to that of topical immunotherapy. The percentage of patients showing regrowth 
of hair during treatment with dapsone was comparable with the occurrence of spontaneous 
regrowth of hair reported in the literature.
Alopecia areata (AA) is a disorder of unknown cause, cardiopulmonary disease were excluded from treat-
t
although evidence for an autoimmune aetiology con- ment with dapsone. Table 1 summarizes the composi-
tinues to mount.1 Various therapies have been reported tion of the two treatment groups. Eleven patients in the
to be effective: photochemotherapy,2 topical and sys- dapsone treatment group had been treated previously
temic corticosteroids,3,4 topical and oral cyclosporin A,5,6 with topical immunotherapy. In eight of these patients,
topical and oral minoxidil,7’8 and isoprinosine.9 None of topical immunotherapy had been successful initially,
these treatments, however, has produced a substantial 
regrowth of hair in the majority of patients. During the 
last decade, controlled studies have shown conclusively 
that the treatment of AA by topical immunotherapy 
using the contact allergen diphenylcyclopropenone
(DCP) is effective.10,11 Disadvantages of topical immu-
notherapy are that it requires close supervision, and the 
treatment is time-consuming for the patients and 
medical staff.
In 1990 Knauber and Zaun12 reported that treat­
ment of AA with dapsone was as effective as topical 
immunotherapy. However, no consensus has been
reached on the value of dapsone for patients with 
1 ^
AA. The purpose of the present study was to analyse 
the effectiveness of dapsone in AA, and to compare the 
results with the response to topical immunotherapy 
obtained at the Nijmegen Institute.10,14
Methods
Between January 1992 and August 1993, 27 patients 
with severe AA were treated with dapsone. Between 
March 1986 and October 19 8 9, a group of 13 9 patients 
with severe AA had been treated with DCP at the 
Nijmegen Institute.10 Informed consent was obtained 
from all patients.
Included in both groups were patients suffering 
from severe AA. Pregnant women and those wishing 
to become pregnant were excluded. Patients with
but a relapse had occurred during prolonged treatment. 
The details of patients treated with DCP have been 
reported previously.10,14
Dapsone was started at a daily dosage of 100 mg. If 
side-effects such as nausea, headache, sleep disturb­
ance, anaemia or methaemoglobinaemia occurred, the 
dosage was reduced to 50 mg daily, or the drug was 
stopped. This dosage was continued until cosmetically 
acceptable hair growth had appeared. The dosage was 
then slowly reduced to the minimum effective level. If, 
after 12 months, no hair growth had occurred, therapy 
was stopped. Before treatment, we checked the full 
blood count, and performed renal and hepatic function 
tests. These parameters, and the methaemoglobin level, 
were monitored during treatment. Topical immu­
notherapy was carried out according to standardized 
procedures.10,14
Hair regrowth was recorded as follows: if some 
regrowth of hair occurred the response was designated 
as ‘hair growth’, and if the regrowth was complete the 
response was recorded as ‘complete hair growth’.
Results
Data on hair growth during treatment with dapsone are 
summarized in Tables 2-4. Of the seven patients with 
the patchy type of AA, four showed complete regrowth. 
Fourteen patients in the dapsone-treated group showed 
sporadic hair growth on the scalp. Of these 14 patients,
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Table 1. Composition of study populations
Treatment Number of patients Sex (M/F) Duration of AA (years) Type of AA
Dapsone 27 15/12 < 1: 2 (7%) 
2-9: 15 (56%) 
10-39: 10 (37%)
Patchy: 7 
ST/T/ST-U/U: 20
D cp10,14 139 66/73 < 1: 36 (26%) 
2-9: 54 (39%) 
10-39: 47 (34%)
Patchy: 44 
ST/T/ST-U/U: 8 5 
Diffuse/ophiasis: 10
ST/T/ST-U/U, subtotal/total/subtotal universalis/universalis; AA, alopecia areata,
Table 2. Patient data during dapsone therapy
Age
Duration of 
disease 
(years) Severity
f
Earlier treatment
Hair
growth
scalp
Hair
growth
body
Complete
hair
growth
Duration of 
dapsone 
therapy 
(months)
Female patients 
(n = 12)
31 25 U top. imm. 1H«« k < 7
37 5 ST-U top. imm. + + 10
33 22 U PUVA, top. imm. + + 8
46 2 U t.s. ----- — — 12
32 5 P PUVA. t.s. + ----- *h|m 10
57 6 ST-U PUVA, t.s„ s.s., top. imm. — — 9
54 11 u t.s. — **** 9
29 11 u minoxldll tmm 9
22 20 p top. Imm., t.s. H"* _ + 12
41 3 months p « + — 8
42 14 ST-U PUVA, t.s, + — 11
52 42 P PUVA, top. Imm. — — 5
Male patients 
{n — 15)
20 2 ST-U 4
21 6 II t.s., top. Imm. + * m m i 12
31 2 U s.s. + — 12
18 9 ST-U M M M P « ■ M 12
46 33 u — — « K B » 12
40 2 U KBMi + — 12
55 4 II top. Imm. d fC X S tH — 4
22 p t.s. — — 6
41 33 u PUVA — — — 11
38 14 u PUVA, top. Imm. 16
25 3 p t.s. — — 6
28 1 ST-U — « — 12
36 2 ST-U PUVA + + « 12
26 6 P t.s., top. Imm. — ■v|«t 12
28 5 u PUVA, top. imm. — * 10
ST/T/ST-U/U, subtotal/total/subtotal universalis/universalis.
P, patchy hair loss confined to scalp. Complete hair growth in the patchy group refers to the scalp only.
t.s., topical steroids.
s.s„ systemic steroids.
top. 1mm., topical Immunotherapy.
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Treatment Type of AA
No. of 
patients
Hair
growth
Complete hair 
growth (%)
Dapsone Patchy 7 4 4 (57-1)
ST/T/ST-U/U 20 10 2 (10-0)
Dcp10.1^ Patchy 44 34 (77-3)
ST/T/ST-U/U 85 33 (38-8)
Diffuse/ophiasis 10 3 (30-0)
Spontaneous15,16 Patchy 20 12 (60)
Totalis 138 47 14 (10)
Table 3. Hair growth during treatment
ST/T/ST-U/U, subtotal/total/subtotal universalis/universalis; AA, alopecia areata.
eight also noticed sparse hair growth all over the body, 
which subsequently disappeared. In the totalis/univer­
salis group, 10 patients showed some hair growth, but 
only two had complete regrowth. In these two patients 
the hair growth appeared after 1 and 5 months, and 
therapy was stopped at 10 and 8 months, respectively, 
because of headache and fatigue, it is notable that the 
hair growth was unaffected by discontinuation of dap- 
sone. Table 4 summarizes the duration of the DCP and 
dapsone treatment phases. It can be seen that improve­
ment during dapsone therapy initially occurred after 
2-2 db 0-6 months in 14 patients, and that cosmetically 
acceptable regrowth was seen after 10 ± 0-7 months in 
six patients. No significant correlation was observed 
between the dosage of dapsone and its clinical efficacy. 
Notably, those patients in the totalis/universalis group 
who had regrowth of hair received dapsone 50 mg daily.
Topical immunotherapy with DCP was continued 
for a year in 139 patients.10,14 If, after this duration 
of therapy, cosmetically acceptable regrowth had not 
occurred, treatment was stopped. Data on hair regrowth 
during immunotherapy are presented in Tables 3 and 4. 
Of the 44 patients with the patchy type of AA, 34 had 
complete hair regrowth, and of the 85 patients with 
subtotalis/totalis type of AA, 33 had complete hair 
regrowth. As topical immunotherapy is initiated on 
one side of the scalp, a unilateral response can be 
interpreted as a therapeutic success, and a bilateral 
response as spontaneous regrowth. Of the 139 patients, 
107 had a unilateral response and none showed a 
bilateral response.
A period of topical immunotherapy of approximately 
3 months was required before signs of regrowth 
occurred, and at least 6 months for complete 
regrowth. A comparison of the effectiveness of dapsone 
with topical immunotherapy revealed that complete 
regrowth occurred in 22 and 50% of the patients, 
respectively. It can be concluded that topical immu­
notherapy is significantly more effective than dapsone 
(Fisher’s exact test: P ^  0-006).
Side-effects are listed in Table 5. In two of 2 7 patients 
treated with dapsone (7%), the dose was reduced 
because of an increase in methaemoglobin ( ^  5%). In 
10 patients the dose was lowered to 50 mg because of a 
reduction of haemoglobin of more than 1 • 6 g% in 2 
weeks. Liver and renal function tests remained normal 
during treatment. Three patients complained of short­
ness of breath, and two had headache. One patient had 
a sleep disorder, another had nausea, and fatigue was 
reported by three patients. In addition to the cutaneous 
side-effects, sleep disturbance proved to be a significant 
problem during topical immunotherapy.
Discussion
lasting AA with dapsone is less successful than topical 
immunotherapy (Fisher's exact test: P < 0 006). As the 
present investigation was not a placebo-controlled 
study, the response to dapsone has to be interpreted in 
the light of the spontaneous recovery rate in alopecia 
areata.15,16 The two patients who had complete regrowth
Treatment Duration until Duration until
period first improvement full remission
Dapsone 20 2'2 ± 0'6 10 ±0-7
Dipheny lcyclopropenone10 43 3'2 ± 0-2 > 6
Table 4. Duration of treatment phases 
(months, mean ± SBM)
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Table 5. Side-effects
Side-effects during 
treatment with dapsone (%)
Side-effects during treatment 
with diphènylcyclopropenone (%)
Nausea 1 (4) Mild contact eczema 139 (100)
Vomiting - Severe eczema/blister formation 81 (58-3)
Headache 2 (7) Disseminated contact eczema 11 (7*9)
Weakness - Urticaria 7 (5'0)
Fatigue 3 (11) Swelling of the scalp 1 (0'7)
Dizziness 1 (4) Oedema of the eyelids/face 5 (3*6)
Shortness of breath 3 (11) Erythema multlforme-like eruption 2 (1*4)
Sleep disorder 1 (4) Lymphadenopathy 139 (100)
Anaemia 10 (37) Sleep disturbance 48 (36*9)
Methaemoglobinaemla 2(7) Headache 3 (2*3)
Cyanosis 1 (4)
Leucopenla -
Agranulocytosis
Hepatotoxlclty -
Nephrotoxicity
Peripheral neuropathy -
Dapsone hypersensitivity syndrome
of hair during dapsone therapy were treated with a low 
dose (50 mg daily), and did not relapse following 
discontinuation of dapsone. Hence, spontaneous recov­
ery could be the explanation for the favourable course 
in both patients.
Table 3 includes the observations of Tosti et al. with 
regard to spontaneous regrowth in patients with the 
patchy type of A A. Complete regrowth in this group 
occurred in 60% of the patients.15 In the patients with 
patchy AA treated with dapsone in the present study, 
four of seven (57%) had a cosmetically acceptable hair 
regrowth. In patients with AA totalis/universalis, 
Muller and Winkelmann reported complete regrowth 
without treatment in 10%.16 This is equivalent to the 
proportion of our dapsone-treated patients in whom 
complete regrowth occurred. Hence, these data cast 
considerable doubt on the therapeutic efficacy of 
dapsone in A A.
The pathogenesis of AA Is still unclear, but there is 
considerable evidence that an immunological mechan­
ism is involved. Numerous reports have documented 
the frequent coexistence of AA with other autoimmune 
disorders,17 and its association with circulating auto­
antibodies against various tissues.18,19 In addition,
more generalized disturbances in the immune status
2 (\ 2]
of patients with AA have been reported. ’
Peribulbar accumulation of lymphocytes occurs in 
AA, and these consist predominantly of T-helper cells,22 
with a CD4/CD8 ratio of approximately 4: l .23 Class I 
and II MHC antigens are expressed by the hair matrix 
cells and subinfundibular epithelium, and an Increased
number of Langerhans cells occurs in the peribulbar 
and intrabulbar regions.24 Topical immunotherapy 
with DCP results in a change of the CD4/CD8 ratio 
from 4:1 to 1:1. The number of Langerhans cells is 
markedly reduced, as is the expression of class I and 
class II MHC antigens.24
Dapsone has potent anti-inflammatory actions, and is 
an effective treatment for dermatitis herpetiformis, 
pustular dermatoses and vasculitis. It interferes with 
the chemotaxis of polymorphonuclear leucocytes and 
the respiratory burst of these cells.26 There is little infor­
mation about the effect of dapsone on T-cell function. It 
has been demonstrated by Wozel that phytohaemag- 
glutinin-induced T-cell transformation is inhibited by 
dapsone.27 However, T cell-mediated diseases show a 
poor response to dapsone therapy. The negative 
results of dapsone therapy in AA lend support to 
the supposition that AA is a T-cell-mediated disease.
In conclusion, the results of the present study do not 
provide any justification for the treatment of AA with 
dapsone, as its efficacy remains doubtful and Its side- 
effects may be troublesome.
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